Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Zami Aberman

Zami Aberman

Executive chairman, Pluristem

Zami Aberman serves as Executive Chairman of the Board, joined Pluristem in September 2005, and redirected the Company's strategy towards cellular therapeutics to become one of the global leaders in the industry. Mr. Aberman's vision to use the maternal portion of the placenta as a cell source for Pluristem’s products, combined with Pluristem's 3D culturing technology, led to the development of the Company's unique therapies. Since October 2015 he serve as a Director of The Alliance for Regenerative Medicine (ARM). In 2013 the World Stem Cells Regenerative Medicine Congress ranked Mr. Aberman as one of the 50 most influential people in the stem cells space. In addition to his current role at Pluristem, Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company in 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd